Therapix Biosciences Ltd. | CIK:0001611746 | 3

  • Filed: 4/30/2018
  • Entity registrant name: Therapix Biosciences Ltd. (CIK: 0001611746)
  • Generator: GoXBRL
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1611746/000121390018005176/0001213900-18-005176-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1611746/000121390018005176/trpx-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001611746
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory

    e.Financial instruments:

     

    1.Financial assets:

     

    Financial assets within the scope of IAS 39 (accounts receivable) are initially recognized at fair value plus directly attributable transaction costs.

     

    After initial recognition, accounts receivable are measured at amortized cost.

     

    2.Financial liabilities:

     

    Financial liabilities are initially recognized at fair value. Loans and other liabilities measured at amortized cost are presented net of direct transaction costs.

     

    After initial recognition, the accounting treatment of financial liabilities is based on their classification as follows:

     

    Financial liabilities at amortized cost:

     

    After initial recognition, loans and other liabilities are measured based on their terms at amortized cost less directly attributable transaction costs using the effective interest method.

     

    3.Offsetting of financial instruments:

     

    Financial assets and financial liabilities are offset and the net amount is presented in the consolidated statement of financial position if there is a legal enforceable right to offset the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.

     

    The right of offset must be legally enforceable not only during the ordinary course of business of the parties to the contract but also in the event of bankruptcy or insolvency of one of the parties. In order for the right of offset to be currently available, it must

    not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that will cause the right to expire.

     

    4.Issue of a unit of securities:

     

    The issue of a unit of securities involves the allocation of the proceeds received (before issuance expenses) to the securities issued in the unit based on the following order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issuance costs are allocated to each component pro rata to the amounts determined for each component in the unit.

     

    5.Derecognition of financial instruments:

     

    a)Financial assets:

     

    A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire or the Company has transferred its contractual rights to receive cash flows from the financial asset or assumes an obligation to pay the cash flows in full without material delay to a third party and has transferred substantially all the risks and rewards of the asset, or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

     

    b)Financial liabilities:

     

    A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires.

     

    6.Impairment of financial assets:

     

    The Company assesses at each reporting date whether there is any objective evidence of impairment of a financial asset or group of financial assets as follows:

     

    Financial assets carried at amortized cost:

     

    Objective evidence of impairment exists when one or more events that have occurred after initial recognition of the asset have a negative impact on the estimated future cash flows. The amount of the loss recorded in profit or loss is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not yet been incurred) discounted at the financial asset’s original effective interest rate. If the financial asset has a variable interest rate, the discount rate is the current effective interest rate. In a subsequent period, the amount of the impairment loss is reversed if the recovery of the asset can be related objectively to an event occurring after the impairment was recognized. The amount of the reversal, up to the amount of any previous impairment, is recorded in profit or loss.